Recro Pharma, Inc. (REPH) Major Shareholder Sells $458,372.36 in Stock

Recro Pharma, Inc. (NASDAQ:REPH) major shareholder Healthcare Master Fun Broadfin sold 47,549 shares of the company’s stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $9.64, for a total transaction of $458,372.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Thursday, November 30th, Healthcare Master Fun Broadfin sold 222,616 shares of Recro Pharma stock. The shares were sold at an average price of $9.58, for a total transaction of $2,132,661.28.
  • On Tuesday, November 21st, Healthcare Master Fun Broadfin sold 102,440 shares of Recro Pharma stock. The shares were sold at an average price of $9.50, for a total transaction of $973,180.00.
  • On Friday, November 24th, Healthcare Master Fun Broadfin sold 172,208 shares of Recro Pharma stock. The shares were sold at an average price of $9.45, for a total transaction of $1,627,365.60.

Shares of Recro Pharma, Inc. (REPH) opened at $9.91 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50. Recro Pharma, Inc. has a 1-year low of $5.81 and a 1-year high of $9.96.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Janney Montgomery Scott LLC increased its holdings in Recro Pharma by 76.9% during the second quarter. Janney Montgomery Scott LLC now owns 22,085 shares of the specialty pharmaceutical company’s stock worth $155,000 after buying an additional 9,600 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Recro Pharma in the first quarter valued at approximately $156,000. Teachers Advisors LLC bought a new position in shares of Recro Pharma in the second quarter valued at approximately $162,000. California State Teachers Retirement System bought a new position in shares of Recro Pharma in the second quarter valued at approximately $169,000. Finally, KCG Holdings Inc. bought a new position in shares of Recro Pharma in the first quarter valued at approximately $173,000. Institutional investors and hedge funds own 61.55% of the company’s stock.

A number of equities research analysts have recently commented on REPH shares. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $8.25 price objective on the stock in a research note on Wednesday, August 16th. Piper Jaffray Companies reissued a “buy” rating and set a $11.00 target price on shares of Recro Pharma in a research note on Friday, October 27th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $11.65.

WARNING: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/03/recro-pharma-inc-reph-major-shareholder-sells-458372-36-in-stock.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

What are top analysts saying about Recro Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Recro Pharma Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit